<DOC>
	<DOCNO>NCT02078102</DOCNO>
	<brief_summary>The trial open label Simon optimal two-stage Phase II trial fix dos oral meloxicam subcutaneous filgrastim ass safety efficacy mobilize autologous peripheral blood stem cell ( PBSC ) multiple myeloma ( MM ) non-Hodgkin 's lymphoma ( NHL ) patient plan undergo high-dose chemotherapy stem cell support . Clinical data regard cellular composition function graft mobilize combination obtain .</brief_summary>
	<brief_title>A Phase II Trial Using Meloxicam Plus Filgrastim Patients With Multiple Myeloma Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Meloxicam</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>A patient must meet follow inclusion criterion eligible enrollment study : 1 . Has provide write informed consent prior complete study procedure . 2 . Patients must previously document histologic diagnosis multiple myeloma ( MM ) nonHodgkin 's lymphoma ( NHL ) , eligible undergo autologous PBSC transplantation institutional protocol . 1 . Multiple myeloma first second partial response well , define International Myeloma Working Group criteria.50 2 . NonHodgkin 's lymphoma must either first second partial response well one follow histology : Diffuse large B cell lymphoma Transformed lymphoma Mantle cell lymphoma Follicular lymphoma ( grade ) Peripheral T cell lymphoma 3 . Age ≥18 ≤75 year time consent . 4 . Karnofsky performance status least 70 % . 5 . Adequate organ function define : 1 . Left ventricular ejection fraction ≥45 % 2 . Corrected DLCO ≥50 % 3 . Serum bilirubin , AST ( aspartate aminotransferase ) ALT ( alanine aminotransferase ) ≤ twice upper limit normal 4 . Serum creatinine ≤ 2.0 mg/dl 5 . Urine Mprotein ≤1 g/24 hour ( MM patient ) 6 . No prior attempt mobilize PBSC . 7 . Patients must least 4 week last cytotoxic chemotherapy ( include alkylating , anthracyclines , epipodophylatoxins , platinum drug ) , immunomodulatory drug ( include lenalidomide pomalidomide , related derivative ) time treatment protocol . 8 . Patients must least 2 week last treatment proteasome inhibitor ( e.g. , bortezomib , carfilzomib ) time treatment protocol . 9 . Patients must negative HIV . 10 . Women childbearing potential must negative pregnancy test ( urine serum ) must lactate time informed consent . 1 . Women men must use adequate birth control take part study ( condom diaphragm contraceptive cream/jelly , birth control pill , Norplant , abstinence ( sexual intercourse ) surgical sterilization . Exclude patient follow condition observe : 1 . Patients must receive radiation therapy within past 4 week , 20 % hematopoiesis form bone ( spine , pelvis proximal long bone ) . 2 . Patients must active central nervous system involvement . 3 . Patients must prior autologous , syngeneic allogeneic hematopoietic stem cell transplant . 4 . Patients must receive prior bone seek radionuclides . 5 . Patients must receive myeloid growth factor within 2 week mobilization attempt study . 6 . Patients must take nonsteroidal antiinflammatory drug ( NSAID ) past 14 day treatment protocol . 7 . Patients must active recent peptic ulcer disease within past 6 month . ) Patients active significant symptom dyspepsia exclude . 8 . Patients history asthma exclude potential NSAID precipitate asthma patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>